NanoString, Abcam expand relationship

NanoString Technologies (NSTG) and Abcam (ABCM) announced the expansion of their long-standing relationship with a new agreement to co-market Abcam antibodies for NanoString’s high-plex spatial multiomic solutions. Under the terms of the agreement, Abcam RabMAb recombinant antibodies will be commercialized as part of the first 64-plex protein panel for NanoString’s CosMx Spatial Molecular Imager. Jointly developed and validated by NanoString and Abcam, the human immuno-oncology panel is the first on the market to combine high-plex spatial proteomic and transcriptomic analyses at single-cell and subcellular resolution. This provides unprecedented insights into immune cells, tumors and their neighborhood and aims to accelerate immune-oncology research supporting a better understanding of clinical response and therapeutic resistance.